A promising pipeline of diverse molecular structures

Pipeline

QBiotics has identified significant unmet medical needs and market opportunities in a range of therapeutic areas.

Our current focus is on treating solid tumours and chronic wounds, with additional early programmes in antibiotics and anti-inflammatories.

Our anticancer drug candidate, tigilanol tiglate, is an intratumoural, oncolytic small molecule with potential in the treatment of a wide range of solid tumours. Tigilanol tiglate is currently in clinical Phase II development for the treatment of soft tissue sarcomas (USA) (awarded FDA Orphan Drug Designation) and head and neck cancers (UK and Australia).

Our wound healing drug candidate, EBC-1013, is a topically applied, semi-synthetic small molecule, that has the potential for the treatment of a wide range of chronic and acute wounds and burns. EBC-1013 is soon to enter a clinical Phase I safety trial in patients with venous leg ulcers.